Wall Street expects a year-over-year decline in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 5, might help the stock move higher if these key numbers are better ...